7-azaindole compound as well as synthesis method and application thereof

By using 7-azaicindole compounds as fluorescence polarization probes and degradation probes for CSN5, the difficulties in screening and research of CSN5 inhibitors were solved, high accuracy and cellular inhibitory activity were achieved, and CSN5-related drug development and diseases were provided. The potential of treatment.

CN119019389AActive Publication Date: 2024-11-26SICHUAN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411129808.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-06-05
Filing Date
2024-08-16
Publication Date
2024-11-26
Estimated Expiration
2044-08-16

AI Technical Summary

Technical Problem

The lack of effective CSN5 inhibitor screening system and degradation probes in the prior art makes it difficult to study the biological function and disease correlation of CSN5, and the CSN complex has a large molecular weight and complex composition, making it difficult to express and purify.

Method used

Provide a 7-azaicindole compound and its synthesis method. It is used as a fluorescent polarization probe and a degradation chemical probe targeting CSN5. It uses its high binding affinity with CSN5 to establish a screening system, which solves the in vitro active system of CSN5. and demonstrates better enzyme-level activity and cell-inhibiting activity.

Benefits of technology

Highly accurate and easy-to-operate screening of CSN5 inhibitors provides the basis for the research and development of novel CSN5 inhibitors and has potential in cancer immunopharmaceutical discovery and treatment of other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019389A_ABST
    Figure CN119019389A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of anti-cancer drugs, and discloses a 7-azaindole compound as well as a synthesis method and application thereof, and the structure of the 7-azaindole compound is as follows: # imgabs 0 #. The 7-azaindole compound can be used as a fluorescence polarization probe or a degradation chemical probe targeting CSN5; wherein the fluorescence polarization chemical probe and the metalloproteinase CSN5 have good binding affinity, and an important foundation is laid for discovery of a novel CSN5 inhibitor; meanwhile, the degradation chemical probe shows good enzyme level activity and cell inhibition activity, has the potential of degrading CSN5 protein and variants, provides a material basis for research and development of related drugs targeting CSN5 and research of biological functions, and has great potential in discovery of cancer immune drugs and treatment of other related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the technical field of anticancer drugs, for example, to a 7-azaindole compound and a synthesis method and use thereof. Background Art

[0002] CSN5 was originally discovered as a coactivator of C-Jun protein, also known as Jab1, and was later found to be the core catalytic subunit of the COP9 signaling body. The main biological function of CSN5 is to remove the NEDD8 molecule bound to the Cullin protein in the active Cullin-RINGE3 ubiquitin ligase complex in the form of a COP9 complex, resulting in the disintegration and inactivation of CRLs and the loss of ubiquitination ability; NEDD8 is a ubiquitin-like protein, so CSN5 is considered to be a deubiquitinating enzyme. Currently, CSN5 has been found to be associated with the occurrence of many cancers. The main reason is that abnormally expressed CSN5 affects the de-NEDD process, thereby affecting the balance of oncogenic factors and tumor suppressor factors regulated by CRLs, such as promoting the degradation of SCF-mediated tumor suppressor factors such as p27, p53, and p57, enhancing the stability of the oncogenic factor HIF-1α, and through CUL4 DCAF Negatively regulate proteins related to DNA damage repair. These abnormal regulatory processes are also closely related to poor prognosis and resistance to anti-tumor drugs. Experiments have shown that knocking out the CSN5 gene inhibits the growth of tumor cells. Therefore, CSN5 is considered a potential new target for tumor treatment. To date, only a few types of CSN5 inhibitors have been reported, including natural products curcumin and berberine, as well as tetrahydroimidazole azepines and 7-azaindole developed by Novartis, and no inhibitors have entered the clinical research stage. In addition, some people believe that the CSN complex may serve as a "docking platform" for each subunit, and its core catalytic subunit CSN5 may also exist in monomeric form, and each subunit or subcomplex may have unique biological functions. CSN5 was found in different oligomeric states in vitro and in cell lysates, and there were two different dimer crystals, which also provided evidence for the possible existence of small complexes. Therefore, the CSN complex may have subcomplexes composed of various subunits, and its core catalytic subunit CSN5 may also exist in monomeric form, and each subunit or subcomplex may have unique biological functions. At the same time, due to the large molecular weight, complex composition and difficulty in expression and purification of the CSN5 complex and its catalytic substrate CRLs-NEDD8 complex, it is difficult to establish a test system based on the biological activity of CSN5 catalytic removal of NEDD8, which greatly limits the discovery of new CSN5 inhibitors. Therefore, there is currently a lack of fluorescent chemical probes to establish a rapid CSN5 inhibitor discovery experimental platform, and there is also a lack of degradation probes to study the biological functions and disease relevance of CSN5 monomers or subcomplexes formed with other subunits. Summary of the invention

[0003] The purpose of the present disclosure is to overcome the deficiencies of the prior art and to provide a 7-azaindole compound and a synthesis method and use thereof, which can provide a material basis for the development of related drugs targeting CSN5 and the study of biological functions, and at the same time have great potential in the discovery of cancer immunotherapy drugs and the treatment of other related diseases.

[0004] The purpose of this disclosure is achieved through the following technical solutions:

[0005] In one aspect, a 7-azaindole compound is provided. The 7-azaindole compound has a structure as shown in Formula I:

[0006]

[0007] In the formula, R1 is selected from phenyl, pyridyl or thienyl;

[0008] L is selected from as well as wherein X is selected from a hydrogen atom, an alkyl group, 5-fluorescein isothiocyanate, or a protein ligand of an E3 ubiquitin ligase complex.

[0010] In some embodiments, X is selected from the protein ligands selected from as well as One of them.

[0011] In some embodiments, L is selected from as well as One of them.

[0013] In some embodiments, R1 is selected from said phenyl.

[0014] In some embodiments, X is selected from said hydrogen atom.

[0015] In some embodiments, L is selected from as well as One of them.

[0016] In some embodiments, the 7-azaindole compound has a structure as shown in any one of Formula L1 to Formula L41:

[0017]

[0018]

[0019]

[0020] In some examples, the 7-azaindole compound has a structure as shown in any one of Formula L20, Formula L22, Formula L27 to Formula L31, Formula L34, Formula L36, Formula L37 and Formula L40.

[0021] On the other hand, a method for synthesizing the 7-azaindole compound as described in any one of the above embodiments is provided. The method comprises the following steps:

[0022] S1.

[0023] Compound 1 and compound 2 are subjected to substitution reaction to obtain compound 3;

[0024] S2.

[0025] The 7-azaindole compound I is synthesized based on the compound 3.

[0026] In some examples, the synthesis of the 7-azaindole compound I based on the compound 3 in S2 comprises the following steps:

[0027] S11.

[0028] Subjecting the compound 3 to a desulfonylation reaction to obtain a compound 4;

[0029] S12.

[0030] Subjecting the compound 4 to a Duff reaction to obtain a compound 5;

[0031] S13.

[0032] The 7-azaindole compound I is synthesized based on the compound 5.

[0033] In some other examples, the synthesis of the 7-azaindole compound I based on the compound 3 in S2 comprises the following steps:

[0034] S21.

[0035] The compound 3 is subjected to iodination reaction to obtain compound 7;

[0036] S22.

[0037] Subjecting the compound 7 to a Sonogashira coupling reaction to obtain a compound 8;

[0038] S23.

[0039] The 7-azaindole compound I was synthesized based on the compound 8.

[0040] In another aspect, a use of the 7-azaindole compound described in any one of the above embodiments or the method described in any one of the above embodiments in preparing an anticancer drug is provided.

[0041] In some embodiments, the 7-azaindole compounds are used to screen and / or screen for CSN5 inhibitors.

[0042] Exemplarily, the 7-azaindole compound is used to screen CSN5 inhibitors. For example, when X is selected from 5-fluorescein isothiocyanate, the 7-azaindole compound is used to prepare a fluorescence polarization probe targeting CSN5.

[0043] Exemplarily, the 7-azaindole compound is used to prepare a CSN5 inhibitor. For example, when X is selected from the protein ligand of the E3 ubiquitin ligase complex, the 7-azaindole compound is used to prepare a degradation chemical probe targeting CSN5.

[0044] The beneficial effects of the present disclosure are:

[0045] 1. The present invention establishes a screening system for CSN5 inhibitors, which has high accuracy and ease of operation, and solves the problem that it is difficult to establish an in vitro activity system for CSN5.

[0046] 2. The 7-azaindole compounds provided in the present disclosure exhibit good enzyme level activity and cell inhibitory activity when used as degradation chemical probes targeting CSN5, and have the potential to degrade CSN5 protein and variants.

[0047] 3. The present disclosure can provide a material basis for the development of related drugs targeting CSN5 and the study of biological functions, and at the same time has great potential in the discovery of cancer immunotherapy drugs and the treatment of other related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] In order to more clearly illustrate the technical solutions in the present disclosure, the following briefly introduces the drawings required to be used in some embodiments of the present disclosure. Obviously, the drawings described below are only drawings of some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can also be obtained based on these drawings. In addition, the drawings described below can be regarded as schematic diagrams, and are not limitations on the actual process of the method involved in the embodiments of the present disclosure.

[0049] Figure 1 This is a diagram showing the effects of some potential degraders in Experimental Example 3 of the present disclosure on HCT116 cells. DETAILED DESCRIPTION

[0050] The technical solutions in some embodiments of the present disclosure are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present disclosure, not all of the embodiments. Based on the embodiments provided by the present disclosure, all other embodiments obtained by ordinary technicians in this field belong to the scope of protection of the present disclosure.

[0051] When describing some embodiments, the expression "A and / or B" may be used. It is easy to understand that "A and / or B" includes the following three combinations: only A, only B, and a combination of A and B.

[0052] When describing some embodiments, the expressions "at least one of A, B and C" and "at least one of A, B or C" may be used, both of which have the same meaning and include the following combinations of A, B and C: A only, B only, C only, the combination of A and B, the combination of A and C, the combination of B and C, and the combination of A, B and C.

[0053] It should be noted that the raw materials and equipment used in the embodiments of the present disclosure are all known products, which are obtained by purchasing commercially available products.

[0054] 1. Intermediate 3: 4,4,5,5-tetramethyl-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1,3,2-dioxaborolane

[0055]

[0056] Step 1: Synthesis of 2-chloro-5-methyl-1,1'-biphenyl (2)

[0057] Compound 1 (781 mg, 3.8 mmol), phenylboronic acid (927 mg, 7.6 mmol), Pd(Ph3P)4 (219 mg, 0.19 mmol), 2M Na2CO3 (5.7 mL, 11.4 mmol) and 15 mL DME were added to a 100 mL double-necked flask, and reacted at 100 ° C for 16 h under Ar atmosphere. The reaction was monitored by TLC. After the reaction was completed. Cooled to ambient temperature, water (30 mL) and ethyl acetate (20 mL) were added to the mixture, the organic layer was separated, extracted three times, the organic layers were combined, dried over anhydrous Na2SO4, filtered, spin-dried, and purified by column chromatography to obtain intermediate 2 (629 mg, 83%).

[0058] 1H NMR (400MHz, DMSO-d6) δ8.38(dd,J=4.8,1.6Hz,1H),8.12(dd,J=8.5,1.3Hz,2H),8.06(dd,J=7.9,1.7Hz,1H),7.93( d,J=4.0Hz,1H),7.74–7.69(m,1H),7.62(dd,J=8.6,7.1Hz,2H),7.31(dd,J=7.9,4.8Hz,1H),6.85(d,J=4.0Hz,1H).

[0059] Step 2: Synthesis of 4,4,5,5-tetramethyl-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1,3,2-dioxaborolane (3)

[0060] To a 50mL double-necked flask, intermediate 2 (629mg, 3.2mmol), bis-pinacol borate (1.63g, 6.4mmol), Pd2(dba)3 (147mg, 0.16mmol), X-Phos (153mg, 0.032mmol), 2M KOAc (4.8mL, 9.6mmol) and 1,4-dioxane (8mL) were added. The mixture was reacted at 110°C for 1h under Ar atmosphere. The reaction was monitored by TLC. After the reaction was completed. Cooled to ambient temperature, water (30mL) and ethyl acetate (20mL) were added, the organic layer was separated, extracted three times, the organic layers were combined, dried over anhydrous Na2SO4, filtered and spin-dried. Purification by column chromatography (PE / EA=100:1, v / v) gave intermediate 3 (593mg, 63%).

[0061] 1 H NMR (400MHz, DMSO-d6) δ7.52(d,J=7.4Hz,1H),7.42–7.29(m,5H),7.19(d,J=3.5Hz,2H),2.36(s,3H),1.15(s,12H).

[0062] 2. Intermediate 6: 2-iodo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine

[0063]

[0064] Step 1: Synthesis of 1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (5)

[0065] Under Ar atmosphere, 7-azaindole 4 (5.92 g, 50 mmol), TBAB (484 mg, 1.5 mmol), finely ground sodium hydroxide (6 g, 150 mmol) and ultra-dry DCM (115 mL) were added to a dried 250 mL double-necked flask, cooled to 0 ° C in an ice bath, and then benzenesulfonyl chloride (8 mL, 62.5 mmol) was slowly added dropwise. After the addition was completed, the ice bath was removed and stirred at room temperature for 1 h. TLC monitored the reaction. After the reaction was completed, water (50 mL) and DCM (50 mL) were added, the organic layer was separated, extracted three times, the organic layers were combined, dried over anhydrous Na2SO4, filtered and dried, and purified by column chromatography (PE / EA=5:1, v / v) to obtain intermediate 5 (12 g, 93%) as a bright white solid.

[0066] 1 H NMR (400MHz, DMSO-d6) δ8.38(dd,J=4.8,1.6Hz,1H),8.12(dd,J=8.5,1.3Hz,2H),8.06(dd,J=7.9,1.7Hz,1H),7.93( d,J=4.0Hz,1H),7.74–7.69(m,1H),7.62(dd,J=8.6,7.1Hz,2H),7.31(dd,J=7.9,4.8Hz,1H),6.85(d,J=4.0Hz,1H).

[0067] Step 2: Synthesis of 2-iodo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (6)

[0068] Under Ar atmosphere, compound 5 (10 g, 39 mmol) was added to a dried 500 mL double-necked flask, and then 200 mL of ultra-dry tetrahydrofuran was added to dissolve it. The reaction solution was stirred at -60 ° C for 30 min, and LDA (39 mL 2M in THF, 78 mmol) was slowly added dropwise. During the addition, the reaction solution gradually changed from colorless to orange-red. After the addition was completed, -60 ° C was maintained and stirred for 15 min; then iodine (15 g, 58.5 mmol) in ultra-dry tetrahydrofuran solution (100 mL) was added dropwise. During the addition, the color of the reaction solution continued to deepen and finally became brown. After the addition was completed, the reaction was moved to room temperature and reacted overnight. TLC monitored the reaction. After the reaction was completed, 50 mL of water was added to quench the reaction, and then 100 mL of ethyl acetate was added to dilute the reaction solution, washed with sodium thiosulfate solution (w / w, 5%) and saturated sodium chloride, separated the organic phase, extracted three times, combined the organic layers, dried over anhydrous Na2SO4, filtered and spin-dried. Purification by column chromatography (PE / EA=5:1, v / v) gave intermediate 6 (10 g, 66%) as a light yellow solid.

[0069] 1H NMR(400MHz, DMSO-d6)δ8.32(dd,J=4.8,1.7Hz,1H),8.09–8.02(m,2H),7.92(dd,J=7.8,1.7 Hz,1H),7.72(dd,J=8.6,6.4Hz,1H),7.64(t,J=7.8Hz,2H),7.30–7.26(m,1H),7.25(s,1H).

[0070] Example 1: Ethyl (E)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylate (L1)

[0071]

[0072] Step 1: Synthesis of 1-(phenylsulfonyl)-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridine (7)

[0073] To a 250mL double-necked flask, intermediate 3 (3.3g, 11mmol), intermediate 6 (3.9g, 10mmol), Pd(Ph3P)4 (578mg, 0.5mmol), 2M Na2CO3 (35mL, 70mmol), and a mixed solvent of 1,4-dioxane and water (v / v=1:3, 140mL) were added, and the mixture was reacted at 100°C for 12h under Ar atmosphere. The reaction was monitored by TLC. After the reaction was completed. Cooled to ambient temperature, water (50mL) and ethyl acetate (50mL) were added, extracted three times, the organic layers were combined, dried over anhydrous Na2SO4, filtered and spin-dried, and column chromatography (PE / EA=10:1, v / v) was performed to obtain intermediate 7 (3.3g, 78%) as a light yellow solid.

[0074] Step 2: Synthesis of 2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridine (8)

[0075] Add intermediate 7 (3.3 g, 7.8 mmol), sodium tert-butoxide (3 g, 31.2 mmol) and 1,4-dioxane (78 mL) to a 250 mL flask, stir and reflux at 100 ° C for 2 h. Monitor the reaction by TLC. After the reaction is completed. Cool to ambient temperature, add water to quench the reaction, add water (30 mL) and ethyl acetate (20 mL), separate the organic phase, extract three times, combine the organic layers, dry over anhydrous Na2SO4, filter and spin dry, and purify by column chromatography (PE / EA=2:1, v / v) to obtain intermediate 8 (1.2 g, 55%) as a yellow solid.

[0076] 1H NMR (400MHz, DMSO-d6) δ11.69(s,1H),8.12(dd,J=4.7,1.6Hz,1H),7.71(dd,J=7.9,1.6Hz,1H),7.59(d,J=7 .8Hz,1H),7.30(m,4H),7.26–7.19(m,3H),6.96(dd,J=7.8,4.7Hz,1H),5.78(d,J=2.1Hz,1H),2.40(s,3H).

[0077] Step 3: Synthesis of 2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (9)

[0078] Add intermediate 8 (1.2 g, 4 mmol), HMTA (842 mg, 1.5 mmol) and glacial acetic acid (21 mL) to a 100 mL flask and stir under reflux for 6 h. Monitor the reaction by TLC. After the reaction is complete, cool to ambient temperature and dilute with water. A large amount of white solid precipitates. Stir overnight. Filter, wash the filter cake with ice water, dry, and recrystallize from n-hexane to obtain intermediate 9 (951 mg, 76%) as a white solid.

[0079] 1 H NMR (400MHz, DMSO-d6) δ12.69(s,1H),9.47(s,1H),8.33–8.25(m,2H),7.61–7.55(m,1H),7.44–7.36(m,2H),7.29–7.14(m,6H),2.47(s,3H).

[0080] Step 4: Synthesis of ethyl (E)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylate (L1)

[0081] In a 100 mL flask, intermediate 24 (951 mg, 3.1 mmol), ethoxycarbonylmethylenetriphenylphosphine (4.3 g, 12.4 mmol) and ultra-dry toluene (12 mL) were added, stirred and refluxed for 4 h, and the reaction was monitored by TLC. After the reaction was completed, the mixture was concentrated by spin drying and column chromatography (PE / EA=1:1, v / v) was performed to obtain L1 (650 mg, 54%) as a white solid.

[0082] Example 2: Synthesis of ethyl 3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoate (L2)

[0083]

[0084] Compound L1 (132 mg, 0.35 mmol), Pd / C (13.2 mg) and methanol (4 mL) were added to a 25 mL double-necked flask and stirred overnight under a hydrogen atmosphere. The reaction was monitored by TLC. After the reaction was completed, the solvent was dried and column chromatography (DCM / EA = 10:1, v / v) was performed to obtain L2 (110 mg, 83%) as a white solid.

[0085] Example 3: Synthesis of 3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoic acid (L3)

[0086]

[0087] A mixed solution of compound L2 (80 g, 0.2 mmol), sodium hydroxide (128 mg, 3.2 mmol), ethanol and water (v / v=5:1, 4 mL) was added to a 25 mL flask, stirred and refluxed for 5 h, and the reaction was monitored by TLC. After the reaction was completed, water was added to the reaction solution, and the resulting solution was acidified to pH 4-5 with 1 M hydrochloric acid. Solids precipitated and dried to obtain L3 (40 mg, 57%) as a light yellow solid.

[0088] Example 4: Synthesis of (E)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (L4)

[0089]

[0090] Referring to the method for synthesizing L3 from L2 in Example 3, compound L4 (112 mg, 60%) was synthesized using L1 (200 mg, 0.53 mmol) as a raw material.

[0091] It should be understood that the above-mentioned "the method of synthesizing L3 from L2 in Reference Example 3" means that the method of synthesizing L3 from L2 in Example 3 is the same as the reaction principle and reaction conditions of the method of synthesizing L4 from L1 in this example. Therefore, the detailed synthesis steps are not repeated here.

[0092] It should be noted that the description similar to “the method for synthesizing L3 from L2 in Reference Example 3” mentioned below has a similar meaning, and therefore will not be repeated below.

[0093] Example 5: Synthesis of 2-(5-methyl-[1,1'-biphenyl]-2-yl)-3-(phenylethynyl)-1H-pyrrolo[2,3-b]pyridine (L5)

[0094]

[0095] Step 1: Synthesis of 3-iodo-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (10)

[0096] Compound 7 (637 mg, 1.5 mmol), NIS (372 mg, 1.65 mmol) and 7.5 mL DCM were added to the flask and stirred at room temperature for 12 h. The reaction was monitored by TLC. After the reaction was completed, the solvent was dried and purified by column chromatography (PE / EA=5:1, v / v) to obtain 10 (437 mg, 53%) as a white solid.

[0097] Step 2: Synthesis of 2-(5-methyl-[1,1'-biphenyl]-2-yl)-3-(phenylethynyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (11)

[0098] Under Ar atmosphere, 10 (300 mg, 0.55 mmol), Et3N (229 μL, 1.65 mmol) and 2 mL of ultra-dry tetrahydrofuran were added to a dried 25 mL flask, followed by Pd(PPh3)2Cl2 (6 mg, 0.005 mmol) and CuI (3 mg, 0.01 mmol), and finally a tetrahydrofuran solution (2 mL) of phenylacetylene (74 mg, 0.55 mmol) was added dropwise, and stirred at room temperature for 12 h. The reaction was monitored by TLC. After the reaction was completed, the solvent was dried and column chromatography (PE / EA=5:1, v / v) was performed to obtain 11 (100 mg, 35%) as a white solid.

[0099] 1 H NMR (400MHz, DMSO-d6) δ8.37(dd,J=4.8,1.6Hz,1H),8.07(dd,J=7.8,1.7Hz,1H),7.83–7.77(m,2H),7.73–7. 67(m,1H),7.57(t,J=7.9Hz,2H),7.47(d,J=7.7Hz,1H),7.42–7.31(m,10H),7.28–7.22(m,3H),2.49(s,3H).

[0100] Step 3: Synthesis of 2-(5-methyl-[1,1'-biphenyl]-2-yl)-3-(phenylethynyl)-1H-pyrrolo[2,3-b]pyridine (L5)

[0101] Add intermediate 11 (100 mg, 0.2 mmol), sodium tert-butoxide (77 mg, 0.8 mmol) and 5 mL 1,4-dioxane to a flask and reflux at 100 ° C for 2 h. Monitor the reaction by TLC. After the reaction is completed. Cool to ambient temperature, add water (5 mL) and ethyl acetate (5 mL), separate the organic phase, extract three times, combine the organic layers, dry over anhydrous Na2SO4, filter and spin dry. Purify by column chromatography (PE / EA=1:1, v / v) to obtain compound L5 (26 mg, 35%) as a white solid.

[0102] Example 6: Synthesis of 3-((1-methyl-1H-pyrazol-4-yl)ethynyl)-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridine (L6)

[0103]

[0104] Step 1: Synthesis of 3-((1-methyl-1H-pyrazol-4-yl)ethynyl)-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (12)

[0105] Referring to the method for synthesizing 11 from 10 in Example 5, intermediate 12 (120 mg, 41%) was synthesized using intermediate 10 (300 mg, 0.55 mmol) and N-methyl-4-alkynylpyrazole (59 mg, 0.55 mmol) as raw materials.

[0106] Step 2: Synthesis of 3-((1-methyl-1H-pyrazol-4-yl)ethynyl)-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridine (L6)

[0107] Referring to the method for synthesizing L5 from 11 in Example 5, intermediate 12 (120 mg, 0.2 mmol) was used as a raw material to synthesize intermediate L6 (44 mg, 57%).

[0108] Example 7: Synthesis of ethyl (E)-3-(2-(4-methyl-2-(thiophen-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylate (L7)

[0109]

[0110] Step 1: Synthesis of 3-(2-chloro-5-methylphenyl)thiophene (14)

[0111] Under Ar atmosphere, Pd(OAc)2 (25 mg, 0.1 mmol), Sphos (83 mg, 0.2 mmol), K3PO4 (6.4 g, 30 mmol) and 20 mL of toluene were added to a dried 100 mL double-necked flask, and then 3-bromothiophene (938 μL, 10 mmol) and compound 13 (2.6 g, 15 mmol) were added, and refluxed at 90°C for 2 h. The reaction was monitored by TLC and the reaction was completed. The solvent was dried and purified by column chromatography to obtain intermediate 14 (1.9 g, 91%) as a colorless oily liquid.

[0112] 1 H NMR(400MHz, DMSO-d6)δ7.70(dd,J=2.9,1.4Hz,1H),7.63(dd,J=5.0,3.0Hz,1H),7.41( d,J=8.1Hz,1H),7.34(dd,J=5.1,1.5Hz,2H),7.17(dd,J=8.2,2.2Hz,1H),2.32(s,3H).

[0113] Step 2: Synthesis of 4,4,5,5-tetramethyl-2-(4-methyl-2-(thiophen-3-yl)phenyl)-1,3,2-dioxaborolane (15)

[0114] Referring to the method for synthesizing intermediate 3 from intermediate 2, intermediate 15 (1.3 g, 48%) was synthesized using intermediate 14 (1.9 g, 9.2 mmol) and bis-pinacol borate (1.9 g, 18.4 mmol) as raw materials.

[0115] 1 H NMR (400MHz, DMSO-d6) δ7.53(dd,J=4.9,2.9Hz,1H),7.47(d,J=7.6Hz,1H),7.41(dd,J=3. 0,1.4Hz,1H),7.23(s,1H),7.15(ddd,J=9.1,6.2,1.5Hz,2H),2.34(s,3H),1.20(s,12H).

[0116] Step 3: Synthesis of 2-(4-methyl-2-(thiophen-3-yl)phenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (16)

[0117] Referring to the method for synthesizing Intermediate 7 from Intermediate 3 and Intermediate 6 in Example 1, Intermediate 16 (1.4 g, 83%) was synthesized using Intermediate 15 (1.3 g, 4.4 mmol) and Intermediate 6 (1.5 g, 4 mmol) as raw materials.

[0118] Step 4: Synthesis of 2-(4-methyl-2-(thiophen-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine (17)

[0119] Referring to the method for synthesizing Intermediate 8 from Intermediate 7 in Example 1, Intermediate 17 (263 mg, 30%) was synthesized using Intermediate 16 (1.4 g, 3.3 mmol) as a starting material.

[0120] Step 5: Synthesis of 2-(4-methyl-2-(thiophen-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (18)

[0121] Referring to the method for synthesizing intermediate 9 from intermediate 8 in Example 1, intermediate 18 (100 mg, 34%) was synthesized using intermediate 17 (263 mg, 0.9 mmol) as a starting material.

[0122] Step 6: Synthesis of ethyl (E)-3-(2-(4-methyl-2-(thiophen-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylate (L7)

[0123] Referring to the method for synthesizing intermediate 10 from intermediate 9 in Example 1, intermediate 18 (100 mg, 0.3 mmol) was used as a raw material to synthesize L7 (28 mg, 24%).

[0124] Example 8: Synthesis of ethyl (E)-3-(2-(4-methyl-2-(pyridin-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylate (L8)

[0125]

[0126] Step 1: Synthesis of 2-chloro-5-methylphenyl)pyridine (19)

[0127] Under Ar atmosphere, 3-bromopyridine (773 mg, 4.9 mmol), 2-chloro-5-methylphenylboronic acid 13 (1.2 g, 5.8 mmol), Pd(PPh3)4 (567 mg, 0.49 mmol), K2CO3 (4.1 g, 30 mmol) and 50 mL of a mixed solvent of toluene / EtOH / H2O (3:2:1, v / v) were added to a 100 mL flask and refluxed at 100 ° C for 2 h. TLC monitored the reaction. After the reaction was completed. Cooled to ambient temperature, water (30 mL) and ethyl acetate (20 mL) were added to the mixture, the organic phase was separated, extracted three times, the organic layers were combined, dried over anhydrous Na2SO4, filtered and spin-dried. Column chromatography purification (PE / EA=1:1, v / v) gave compound 19 (950 mg, 95%) as a colorless oily liquid.

[0128] 1 H NMR (400MHz, DMSO-d6) δ8.65–8.60(m,2H),7.87(dt,J=7.9,2.0Hz,1H),7.54–7.46(m,2H),7.32–7.24(m,2H),2.35(s,3H).

[0129] Step 2: Synthesis of 3-(5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)phenyl)pyridine (20)

[0130] Referring to the method for synthesizing intermediate 3 from intermediate 2, intermediate 20 (778 mg, 56%) was synthesized using intermediate 19 (950 mg, 4.7 mmol) and bis-pinacol borate (2.4 g, 9.4 mmol) as raw materials.

[0131] Step 3: Synthesis of 2-(4-methyl-2-(pyridin-3-yl)phenyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (21)

[0132] Referring to the method for synthesizing Intermediate 7 from Intermediate 3 and Intermediate 6 in Example 1, Intermediate 21 (563 mg, 55%) was synthesized using Intermediate 20 (778 mg, 2.64 mmol) and Intermediate 6 (920 mg, 2.4 mmol) as raw materials.

[0133] Step 4: Synthesis of 2-(4-methyl-2-(pyridin-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine (22)

[0134] Referring to the method for synthesizing Intermediate 8 from Intermediate 7 in Example 1, Intermediate 22 (274 mg, 75%) was synthesized using Intermediate 21 (563 mg, 1.33 mmol) as a starting material.

[0135] Step 5: Synthesis of 2-(4-methyl-2-(pyridin-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (23)

[0136] Referring to the method for synthesizing intermediate 9 from intermediate 8 in Example 1, intermediate 22 (274 mg, 1 mmol) was used as a starting material to synthesize intermediate 23 (140 mg, 45%).

[0137] Step 6: Synthesis of ethyl (E)-3-(2-(4-methyl-2-(pyridin-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylate (L8)

[0138] Referring to the method for synthesizing intermediate 10 from intermediate 9 in Example 1, intermediate 23 (140 mg, 0.45 mmol) was used as a raw material to synthesize L8 (100 mg, 60%).

[0139] Example 9: Synthesis of ethyl 3-(2-(4-methyl-2-(pyridin-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoate (L9)

[0140]

[0141] Referring to the method for synthesizing L2 from L1 in Example 1, L9 (24 mg, 48%) was synthesized using L8 (50 mg, 0.13 mmol) as a raw material.

[0142] Example 10: Synthesis of N-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thioureacarbonyl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L10)

[0143]

[0144] Step 1: Synthesis of 1-(2-aminoethyl)-3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thiourea (25)

[0145] Dissolve ethylenediamine (42 μL, 0.64 mmol) in 21 mL of methanol, then slowly drop fluorescein isothiocyanate isomer I 24 (250 mg, 0.64 mmol) in methanol (12.5 mL) into the ethylenediamine system. After the addition is complete, stir at room temperature for 3 h. Monitor the reaction by TLC. After the reaction is complete. Dry the solvent under reduced pressure, add methanol to the flask, filter, and dry the filter cake to obtain intermediate 25 (127 mg, 46%) as an orange-red powder.

[0146] Step 2: Synthesis of N-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thioureacarbonyl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L10)

[0147] Add L3 (68 mg, 0.19 mmol) and 2 mL DMF to the flask, stir for 10 min, add HATU (181 mg, 0.48 mmol), stir at room temperature for 30 min, add intermediate 25 (127 mg, 0.29 mmol) and DIPEA (100 μL, 0.57 mmol), stir at room temperature for 18 h. Monitor the reaction by TLC. After the reaction is complete, add a small amount of water to precipitate, filter, and take the filter cake for preparative HPLC to obtain the final product L10 (28 mg, 19%).

[0148] Example 11: Synthesis of N-(3-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thiourea)propyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L11)

[0149]

[0150] Step 1: Synthesis of 1-(3-aminopropyl)-3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thiourea (26)

[0151] Referring to the method for synthesizing intermediate 25 from compound 24 in Example 10, intermediate 26 (400 mg, 79%) was synthesized using propylenediamine (80 μL, 1.1 mmol) and compound 24 (420 mg, 1.1 mmol) as raw materials.

[0152] Step 2: Synthesis of N-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thioureido)propyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L11)

[0153] Referring to the method for synthesizing L10 from L3 and intermediate 25 in Example 10, L11 (70 mg, 16%) was synthesized using L3 (200 mg, 0.56 mmol) and intermediate 26 (400 mg, 0.84 mmol) as raw materials.

[0154] Example 12: Synthesis of N-(4-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thiourea)butyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L12)

[0155]

[0156] Step 1: Synthesis of 1-(4-aminobutyl)-3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thiourea (27)

[0157] Referring to the method for synthesizing intermediate 25 from compound 24 in Example 10, intermediate 27 (200 mg, 50%) was synthesized using dibutyl amine (120 μL, 0.9 mmol) and compound 24 (360 mg, 0.9 mmol) as raw materials.

[0158] Step 2: Synthesis of N-(4-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thioureido)butyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L12)

[0159] Referring to the method for synthesizing L10 from L3 and intermediate 25 in Example 10, L12 (74 mg, 10%) was synthesized using L3 (100 mg, 0.3 mmol) and intermediate 27 (200 mg, 0.4 mmol) as raw materials.

[0160] Example 13: Synthesis of N-((1R,4R)-4-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thiourea)cyclohexyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L13)

[0161]

[0162] Step 1: Synthesis of 1-((1R,4R)-4-aminocyclohexyl)-3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thiourea (28)

[0163] Referring to the method for synthesizing intermediate 25 from compound 24 in Example 10, intermediate 28 (220 mg, 57%) was synthesized using 1,4-cyclohexanediamine (90 mg, 0.77 mmol) and compound 24 (300 mg, 0.77 mmol) as raw materials.

[0164] Step 2: Synthesis of N-((1R,4R)-4-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)thioureido)cyclohexyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanamide (L13)

[0165] Referring to the method for synthesizing L10 from L3 and intermediate 25 in Example 10, L13 (52 mg, 22%) was synthesized using L3 (100 mg, 0.28 mmol) and intermediate 28 (200 mg, 0.4 mmol) as raw materials.

[0166] Example 14: Synthesis of 1-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)-3-(2-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)ethyl)thiourea (L14)

[0167]

[0168] Step 1: Synthesis of tert-butyl (2-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)ethyl)carbamate (29)

[0169] Compound L3 (100 mg, 0.3 mmol), HBTU (180 mg, 0.45 mmol) and 2 mL DMF were added to the flask, stirred at room temperature for 10 min, and then 1-[2-(BOC-amino)ethyl]piperazine (100 mg, 0.39 mmol) and DIPEA (480 μL, 0.9 mmol) were added, and stirred at room temperature for 1 h. The reaction was monitored by TLC. After the reaction was completed. Water (5 mL) and ethyl acetate (5 mL) were added to the mixture, and the organic phase was separated and extracted three times. The organic layers were combined, dried over anhydrous Na2SO4, filtered and dried, and purified by column chromatography to obtain intermediate 29 (136 mg, 82%) as a white solid.

[0170] Step 2: Synthesis of 1-(4-(2-aminoethylpiperazin-1-yl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanone (30)

[0171] Intermediate 29 (100 mg, 0.18 mmol), 2 mL TFA and 3 mL DCM were added to a flask and stirred at room temperature for 1 h. The reaction was monitored by TLC. After the reaction was completed, the solvent was spin-dried to obtain intermediate 30 (80 mg, 0.17 mmol) as a white oily liquid, which was directly used in the next step.

[0172] Step 3: Synthesis of 1-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside]-5-yl)-3-(2-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrazolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)ethyl)thiourea (L14)

[0173] Add intermediate 30 (80 mg, 0.17 mmol) and 2 mL DMF to a flask, then add FITC (86 mg, 0.17 mmol) and DIPEA (187 μL, 0.85 mmol), and stir at room temperature overnight. Monitor the reaction by TLC. After the reaction is complete, the solvent is dried under reduced pressure and separated by preparative HPLC to obtain compound L14 (83 mg, 24%).

[0174] Example 15: Synthesis of N-(4-((3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside)methyl)phenyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyridin-3-yl)propanamide (L15)

[0175]

[0176] Step 1: Synthesis of tert-butyl (4-((3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyridin-3-yl)propionamido)methylbenzyl)carbamate (31)

[0177] Referring to the method for synthesizing intermediate 29 from compound L3 in Example 14, intermediate 31 (109 mg, 78%) was synthesized using 1,4-phenylenediamine (81 mg, 0.34 mmol) and compound L3 (90 mg, 0.25 mmol) as raw materials.

[0178] Step 2: Synthesis of N-(4-aminomethylphenyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyridin-3-yl)propanamide (32)

[0179] Referring to the method for synthesizing intermediate 30 from intermediate 29 in Example 14, intermediate 32 (100 mg, 0.19 mmol) was synthesized using intermediate 31 (109 mg, 0.2 mmol) as a starting material.

[0180] Step 3: Synthesis of N-(4-((3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthoside)methyl)phenyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyridin-3-yl)propanamide (L15)

[0181] Referring to the method for synthesizing compound L14 from intermediate 30 in Example 14, compound L15 (57 mg, 35%) was synthesized using intermediate 32 (100 mg, 0.19 mmol) as a starting material.

[0182] Example 16: Synthesis of N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L16)

[0183]

[0184] Step 1: Synthesis of tert-butyl (2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-isoindolin-4-yl)amino)ethyl)carbamate (34)

[0185] Compound 33 (80 mg, 0.3 mmol) and 2 mL DMSO were added under ice bath conditions, and then N-BOC-ethylenediamine (48 mg, 0.3 mmol) and DIPEA (58 μL, 0.33 mmol) were added, and stirred at 90°C for 4 h. The reaction was monitored by TLC. After the reaction was completed, water (5 mL) and ethyl acetate (5 mL) were added to the reaction solution, and the organic phase was separated and extracted three times. The organic layers were combined, dried over anhydrous Na2SO4, filtered and spin-dried, and purified by column chromatography (PE / EA=2:1, v / v) to obtain intermediate 34 (100 mg, 80%) as a yellow solid.

[0186] Step 2: Synthesis of 1,3-dioxo-isoindoline-2-(2,6-dioxopiperidin-3-yl)-4-di(2-aminoethyl)amine (35)

[0187] Intermediate 34 (100 mg, 0.24 mmol), TFA (2 mL / mmol) and DCM (4 mL / mmol) were added to a flask and stirred at room temperature for 3 h. The reaction was monitored by TLC. After the reaction was completed, the solvent was dried to obtain intermediate 35 as a yellow oily liquid, which was directly used in the next step.

[0188] Step 3: Synthesis of N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L16)

[0189] Compound L3 (40 mg, 0.13 mmol), HBTU (92 mg, 0.19 mmol) and 2 mL DMF were added to the flask, stirred at room temperature for 10 min, and then a mixed solution of intermediate 35 (70 mg, 0.17 mmol), DIPEA (84 μL, 0.39 mmol) and 2 mL DMF was added dropwise, and stirred at room temperature for 1 h. TLC monitored the reaction, and after the reaction was completed. Water (5 mL) and ethyl acetate (5 mL) were added to the mixture, the organic phase was separated, extracted three times, and the organic layers were combined. The organic layer was dried over anhydrous Na2SO4, filtered and spin-dried. Column chromatography gave the final product L16 (43 mg, 51%) as a yellow solid.

[0190] Example 17: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)isoindoline-1,3-dione (L17)

[0191]

[0192] Step 1: Synthesis of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazine-1-carboxylate (36)

[0193] Referring to the method for synthesizing intermediate 34 from compound 33 in Example 16, intermediate 36 (203 mg, 63%) was synthesized using compound 33 (200 mg, 0.73 mmol) and N-Boc piperazine (135 mg, 0.73 mmol) as raw materials.

[0194] Step 2: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(piperazin-1-yl)isoindoline-1,3-dione (37)

[0195] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 37 (130 mg, 0.73 mmol) was synthesized using intermediate 36 (135 mg, 0.73 mmol) as a starting material.

[0196] Step 3: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)isoindoline-1,3-dione (L17)

[0197] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L17 (48 mg, 62%) was synthesized using intermediate L3 (40 mg, 0.13 mmol) and intermediate 37 (75 mg, 0.17 mmol) as raw materials.

[0198] Example 18: Synthesis of N-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisobenzopiperidin-4-yl)piperazin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L18)

[0199]

[0200] Step 1: Synthesis of tert-butyl (2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)ethyl)carbamate (38)

[0201] Referring to the method for synthesizing intermediate 34 from compound 33 in Example 16, intermediate 38 (438 mg, 82%) was synthesized using compound 33 (300 mg, 1.1 mmol) and 1-[2-(BOC-amino)ethyl]piperazine (250 mg, 1.1 mmol) as raw materials.

[0202] Step 2: Synthesis of 4-(4-(2-aminoethyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoquinoline-1,3-dione (39)

[0203] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 39 (434 mg, 0.9 mmol) was synthesized using Intermediate 38 (438 mg, 0.9 mmol) as a starting material.

[0204] Step 3: Synthesis of N-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisobenzopiperidin-4-yl)piperazin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L18)

[0205] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L18 (37 mg, 51%) was synthesized using intermediate L3 (36 mg, 0.1 mmol) and intermediate 39 (62 mg, 0.13 mmol) as raw materials.

[0206] Example 19: Synthesis of N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)amino)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-propionamide (L19)

[0207]

[0208] Step 1: Synthesis of tert-butyl (2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)amino)ethyl)carbamate (41)

[0209] Referring to the method for synthesizing intermediate 34 from compound 33 in Example 16, intermediate 41 (98 mg, 80%) was synthesized using compound 40 (80 mg, 0.3 mmol) and N-BOC-ethylenediamine (48 mg, 0.3 mmol) as raw materials.

[0210] Step 2: Synthesis of 5-((2-aminoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (42)

[0211] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 42 (96 mg, 0.8 mmol) was synthesized using Intermediate 41 (98 mg, 0.8 mmol) as a starting material.

[0212] Step 3: Synthesis of N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)amino)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-propionamide (L19)

[0213] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L19 (50 mg, 77%) was synthesized using intermediate L3 (40 mg, 0.1 mmol) and intermediate 42 (54 mg, 0.13 mmol) as raw materials.

[0214] Example 20: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)isoindoline-1,3-dione (L20)

[0215]

[0216] Step 1: Synthesis of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)piperazine-1-carboxylate (43)

[0217] Referring to the method for synthesizing intermediate 34 from compound 33 in Example 16, intermediate 43 (205 mg, 64%) was synthesized using compound 40 (200 mg, 0.73 mmol) and N-Boc piperazine (135 mg, 0.73 mmol) as raw materials.

[0218] Step 2: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione (44)

[0219] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 44 (200 mg, 0.46 mmol) was synthesized using intermediate 43 (205 mg, 0.46 mmol) as a starting material.

[0220] Step 3: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)isoindoline-1,3-dione (L20)

[0221] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L20 (40 mg, 46%) was synthesized using intermediate L3 (40 mg, 0.1 mmol) and intermediate 44 (75 mg, 0.17 mmol) as raw materials.

[0222] Example 21: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-((2-(4-(3-[(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)ethyl)amino)isoindoline-1,3-dione (L21)

[0223]

[0224] Step 1: Synthesis of tert-butyl 4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)amino)ethyl)piperazine-1-carboxylate (45)

[0225] Referring to the method for synthesizing intermediate 34 from compound 33 in Example 16, intermediate 45 (400 mg, 75%) was synthesized using compound 40 (300 mg, 1.1 mmol) and 4-N-(2-aminoethyl)-1-N-BOC-piperazine (250 mg, 1.1 mmol) as raw materials.

[0226] Step 2: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-((2-(piperazin-1-yl)ethyl)amino)isoindoline-1,3-dione (46)

[0227] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 46 (400 mg, 0.8 mmol) was synthesized using intermediate 45 (400 mg, 0.8 mmol) as a starting material.

[0228] Step 3: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-((2-(4-(3-[(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)ethyl)amino)isoindoline-1,3-dione (L21)

[0229] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L21 (26 mg, 36%) was synthesized using intermediate L3 (36 mg, 0.1 mmol) and intermediate 46 (62 mg, 0.13 mmol) as raw materials.

[0230] Example 22: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyrin-3-yl)propanoyl)azetidin-3-yl)piperazin-1-yl)isoindoline-1,3-dione (L22)

[0231]

[0232] Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(piperazin-1-yl)isoindoline-1,3-dione (37)

[0233] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 37 (490 mg, 1.44 mmol) was synthesized using Intermediate 36 (490 mg, 1.44 mmol) as a starting material.

[0234] Step 2: Synthesis of tert-butyl 3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)azetidine-1-carboxylate (47)

[0235] Intermediate 37 (490 mg, 1.44 mmol) was dissolved in 4 mL DMF, DIPEA (251 μL, 1.44 mmol) and 1-Boc-3-azetidinone (494 mg, 2.88 mmol) were added, and the mixture was stirred at room temperature for 30 min. Glacial acetic acid (290 μL) and NaBH3CN (181 mg, 2.88 mmol) were added to the reaction system, and the mixture was moved to 40°C and stirred overnight. TLC monitored the reaction, and after the reaction was completed. Saturated sodium bicarbonate solution was added to quench the reaction, water (5 mL) and ethyl acetate (5 mL) were added to the mixture, the organic phase was separated, extracted three times, the organic layers were combined, dried over anhydrous Na2SO4, filtered and spin-dried, and column chromatography was performed to obtain intermediate 47 (365 mg, 51%) as a yellow solid.

[0236] Step 3: Synthesis of 4-(4-(azetidin-3-yl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (48)

[0237] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 48 (365 mg, 0.73 mmol) was synthesized using Intermediate 47 (365 mg, 0.73 mmol) as a starting material.

[0238] Step 4: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyrin-3-yl)propanoyl)azetidin-3-yl)piperazin-1-yl)isoindoline-1,3-dione (L22)

[0239] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L22 (34 mg, 36%) was synthesized using intermediate L3 (45 mg, 0.13 mmol) and intermediate 48 (66 mg, 0.17 mmol) as raw materials.

[0240] Example 23: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-((1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionyl)piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione (L23)

[0241]

[0242] Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(piperazin-1-yl)isoindoline-1,3-dione (37)

[0243] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 37 (400 mg, 1.2 mmol) was synthesized using Intermediate 36 (400 mg, 1.2 mmol) as a starting material.

[0244] Step 2: Synthesis of tert-butyl 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)methyl)piperidine-1-carboxylate (49)

[0245] Referring to the method for synthesizing intermediate 47 from intermediate 37 in Example 22, intermediate 49 (317 mg, 48%) was synthesized using intermediate 37 (400 mg, 1.2 mmol) and 1-tert-butyloxycarbonylpiperidine-4-carboxaldehyde (512 mg, 2.4 mmol) as raw materials.

[0246] Step 3: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-(piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione (50)

[0247] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 50 (317 mg, 0.6 mmol) was synthesized using Intermediate 49 (317 mg, 0.6 mmol) as a starting material.

[0248] Step 4: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-((1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionyl)piperidin-4-ylmethyl)piperazin-1-yl)isoindoline-1,3-dione (L23)

[0249] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L23 (30 mg, 11%) was synthesized using intermediate L3 (120 mg, 0.34 mmol) and intermediate 50 (194 mg, 0.44 mmol) as raw materials.

[0250] Example 24: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)azetidin-3-yl)piperazin-1-yl)isoquinoline-1,3-dione (L24)

[0251]

[0252] Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione (44)

[0253] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 44 (470 mg, 1.4 mmol) was synthesized using intermediate 43 (470 mg, 1.4 mmol) as a starting material.

[0254] Step 2: Synthesis of tert-butyl 3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)azetidine-1-carboxylate (51)

[0255] Referring to the method for synthesizing intermediate 47 from intermediate 37 in Example 22, intermediate 51 (424 mg, 61%) was synthesized using intermediate 44 (470 mg, 1.4 mmol) and 1-Boc-3-azetidinone (480 mg, 2.8 mmol) as raw materials.

[0256] Step 3: Synthesis of 5-(4-(azetidin-3-yl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoquinoline-1,3-dione (52)

[0257] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 52 (424 mg, 0.8 mmol) was synthesized using Intermediate 51 (424 mg, 0.8 mmol) as a starting material.

[0258] Step 4: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)azetidin-3-yl)piperazin-1-yl)isoquinoline-1,3-dione (L24)

[0259] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L24 (26 mg, 32%) was synthesized using intermediate L3 (45 mg, 0.13 mmol) and intermediate 52 (84 mg, 0.17 mmol) as raw materials.

[0260] Example 25: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione (L25)

[0261]

[0262] Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(piperazin-1-yl)isoindoline-1,3-dione (44)

[0263] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 44 (400 mg, 0.9 mmol) was synthesized using intermediate 43 (400 mg, 0.9 mmol) as a starting material.

[0264] Step 2: Synthesis of tert-butyl 4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1-carboxylate (53)

[0265] Referring to the method for synthesizing intermediate 47 from intermediate 37 in Example 22, intermediate 53 (420 mg, 85%) was synthesized using intermediate 44 (400 mg, 0.9 mmol) and 1-tert-butyloxycarbonylpiperidine-4-carboxaldehyde (383 mg, 1.8 mmol) as raw materials.

[0266] Step 3: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(4-(piperidin-4-methyl)piperazin-1-yl)isoquinoline-1,3-dione (54)

[0267] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 54 (420 mg, 0.8 mmol) was synthesized using Intermediate 53 (420 mg, 0.8 mmol) as a starting material.

[0268] Step 4: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-5-(4-((1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionyl)piperidin-4-yl)methyl)piperazin-1-yl)isoindoline-1,3-dione (L25)

[0269] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L25 (46 mg, 30%) was synthesized using intermediate L3 (75 mg, 0.2 mmol) and intermediate 54 (140 mg, 0.26 mmol) as raw materials.

[0270] Example 26: Synthesis of N-(2-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)piperidin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L26)

[0271]

[0272] Step 1: Synthesis of 4-(4-(azetidin-3-yl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (48)

[0273] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 48 (600 mg, 1.2 mmol) was synthesized using Intermediate 47 (600 mg, 1.2 mmol) as a starting material.

[0274] Step 2: Synthesis of tert-butyl (2-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoquinolin-4-yl)piperazin-1-yl)aziridine-1-yl)ethyl)carbamate (55)

[0275] 48 (600 mg, 1.2 mmol), N-tert-butyloxycarbonyl-2-aminoacetaldehyde (287 mg, 1.8 mmol) and 10 mL DCM were added to a 25 mL flask, and 9 drops of glacial acetic acid were added. The mixture was stirred at room temperature for 1 h, and EtOH and NaBH3CN (170 mg, 2.7 mmol) were added. The mixture was stirred overnight. The reaction was monitored by TLC. After the reaction was completed, the solvent was dried under reduced pressure, and column chromatography (PE / EA=1:1, v / v) was performed to obtain intermediate 55 (337 mg, 52%) as a white solid.

[0276] Step 3: Synthesis of 4-(4-(1-(2-aminoethyl)indolin-3-yl)piperazin-1-yl)-2-[2,6-dioxopiperidin-3-yl]indole-1,3-dione (56)

[0277] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 56 (337 mg, 0.6 mmol) was synthesized using Intermediate 55 (337 mg, 0.6 mmol) as a starting material.

[0278] Step 4: Synthesis of N-(2-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)piperidin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L26)

[0279] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L26 (47 mg, 18%) was synthesized using intermediate L3 (120 mg, 0.34 mmol) and intermediate 56 (245 mg, 0.44 mmol) as raw materials.

[0280] Example 27: Synthesis of (E)-4-(4-methoxyphenyl)-N-(2-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionamido)ethyl)-4-oxobut-2-enamide (L27)

[0281]

[0282] Step 1: Synthesis of (E)-4-(4-methoxyphenyl)-4-oxobut-2-enoic acid (58)

[0283] Under Ar atmosphere, add maleic anhydride (5g, 51mmol), anisole 57 (5.6mL, 51mmol) and 100mL ultra-dry DCM in the 250mL flask of oven dry, slowly add anhydrous aluminum chloride (13.6g, 102mmol) in batches, reaction solution becomes orange-red from colorless, stirs 4h at room temperature. TLC monitors reaction, after reaction is complete. Reaction solution is poured in iced hydrochloric acid solution, stirred for 10min, water (50mL) and DCM (50mL) are added in the mixture, separated organic layer, extracted three times, merged organic layer, through anhydrous Na SO drying, filtered and spin-dried to obtain intermediate 58 (9.6g, 91%), light yellow solid.

[0284] Step 2: Synthesis of tert-butyl (E)-(2-(4-(4-methoxyphenyl)-4-oxobut-2-enamido)ethyl)carbamate (59)

[0285] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 58 (2 g, 9.8 mmol) and N-BOC-ethylenediamine (2.1 g, 13 mmol) were used as raw materials to synthesize intermediate 59 (2.8 g, 82%).

[0286] Step 3: Synthesis of (E)-N-(2-aminoethyl)-4-(4-methoxyphenyl)-4-oxobut-2-enamide (60)

[0287] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 60 (700 mg, 1.8 mmol) was synthesized using Intermediate 59 (700 mg, 1.8 mmol) as a starting material.

[0288] Step 4: Synthesis of (E)-4-(4-methoxyphenyl)-N-(2-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionamido)ethyl)-4-oxobut-2-enamide (L27)

[0289] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L27 (34 mg, 21%) was synthesized using L3 (100 mg, 0.28 mmol) and intermediate 60 (126 mg, 0.36 mmol) as raw materials.

[0290] Example 28: Synthesis of (E)-1-(4-methoxyphenyl)-4-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)but-2-ene-1,4-dione (L28)

[0291]

[0292] Step 1: Synthesis of tert-butyl (E)-4-(4-methoxyphenyl)-4-oxobut-2-enoylpiperazine-1-carboxylate (61)

[0293] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 58 (1 g, 4.9 mmol) and N-BOC-piperazine (1.2 g, 6.4 mmol) were used as raw materials to synthesize intermediate 61 (1.6 g, 86%).

[0294] Step 2: Synthesis of (E)-1-(4-methoxyphenyl)-4-(piperazin-1-yl)but-2-ene-1,4-dione (62)

[0295] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 62 (350 mg, 0.9 mmol) was synthesized using Intermediate 61 (350 mg, 0.9 mmol) as a starting material.

[0296] Step 3: Synthesis of (E)-1-(4-methoxyphenyl)-4-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-1-yl)but-2-ene-1,4-dione (L28)

[0297] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L28 (80 mg, 40%) was synthesized using L3 (120 mg, 0.34 mmol) and intermediate 62 (164 mg, 0.44 mmol) as raw materials.

[0298] Example 29: Synthesis of (E)-N-(2-(4-(4-methoxyphenyl)-4-oxybut-2-enoyl)piperazin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L29)

[0299]

[0300] Step 1: Synthesis of tert-butyl (E)-2-(4-(4-(4-methoxyphenyl)-4-oxybut-2-enoyl)piperazin-1-yl)ethylcarbamate (63)

[0301] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 58 (800 mg, 3.9 mmol) and 1-[2-(BOC-amino)ethyl]piperazine (1.2 g, 5 mmol) were used as raw materials to synthesize intermediate 63 (900 mg, 56%).

[0302] Step 2: Synthesis of (E)-1-(4-(2-aminoethyl)piperazin-1-yl)-4-(4-methoxyphenyl)but-2-ene-1,4-dione (64)

[0303] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 64 (900 mg, 2.2 mmol) was synthesized using intermediate 63 (900 mg, 2.2 mmol) as a starting material.

[0304] Step 3: Synthesis of (E)-N-(2-(4-(4-methoxyphenyl)-4-oxybut-2-enoyl)piperazin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L29)

[0305] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L29 (34 mg, 19%) was synthesized using L3 (100 mg, 0.28 mmol) and intermediate 64 (151 mg, 0.37 mmol) as raw materials.

[0306] Example 30: Synthesis of (E)-1-(4-methoxyphenyl)-4-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyridin-3-yl)propanoyl)azetidin-3-yl)piperazin-1-yl)but-2-ene-1,4-dione (L30)

[0307]

[0308] Step 1: Synthesis of (E)-1-(4-methoxyphenyl)-4-(piperazin-1-yl)but-2-ene-1,4-dione (62)

[0309] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 62 (3 g, 7.8 mmol) was synthesized using Intermediate 61 (3 g, 7.8 mmol) as a starting material.

[0310] Step 2: Synthesis of tert-butyl (E)-3-(4-(4-(4-methoxyphenyl)-4-oxybut-2-enoyl)piperazin-1-yl)azetidine-1-carboxylate (65)

[0311] Referring to the method for synthesizing Intermediate 47 from Intermediate 37 in Example 22, Intermediate 65 (2 g, 60%) was synthesized using Intermediate 62 (3 g, 7.8 mmol) and 1-Boc-3-azetidinone (2.7 g, 15.6 mmol) as raw materials.

[0312] Step 3: Synthesis of (E)-1-(4-azetidin-3-yl)piperazin-1-yl)-4-(4-methoxyphenyl)but-2-ene-1,4-dione (66)

[0313] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 66 (800 mg, 1.9 mmol) was synthesized using Intermediate 65 (800 mg, 1.9 mmol) as a starting material.

[0314] Step 4: Synthesis of (E)-1-(4-methoxyphenyl)-4-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyridin-3-yl)propanoyl)azetidin-3-yl)piperazin-1-yl)but-2-ene-1,4-dione (L30)

[0315] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L3 (120 mg, 0.34 mmol) and intermediate 66 (189 mg, 0.44 mmol) were used as raw materials to synthesize L30 (37 mg, 17%).

[0316] Example 31: Synthesis of (E)-1-(4-methoxyphenyl)-4-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyrin-3-yl)propionyl)indol-3-yl)piperazinyl)but-2-ene-1,4-dione (L31)

[0317]

[0318] Step 1: Synthesis of (E)-1-(4-methoxyphenyl)-4-(piperazin-1-yl)but-2-ene-1,4-dione (62)

[0319] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 62 (3 g, 7.8 mmol) was synthesized using Intermediate 61 (3 g, 7.8 mmol) as a starting material.

[0320] Step 2: Synthesis of tert-butyl (E)-4-((4-(4-methoxyphenyl)-4-oxobut-2-enoyl)piperazin-1-ylmethyl)-1-piperidinecarboxylate (67)

[0321] Referring to the method for synthesizing intermediate 47 from intermediate 37 in Example 22, intermediate 62 (500 mg, 1.4 mmol) and 1-tert-butyloxycarbonylpiperidine-4-carboxaldehyde (600 mg, 2.8 mmol) were used as raw materials to synthesize intermediate 67 (481 mg, 73%).

[0322] Step 3: Synthesis of (E)-1-(4-methoxyphenyl)-4-(4-(piperidin-4-ylmethyl)piperazin-1-yl)but-2-ene-1,4-dione (68)

[0323] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 68 (481 mg, 1 mmol) was synthesized using Intermediate 67 (481 mg, 1 mmol) as a starting material.

[0324] Step 4: Synthesis of (E)-1-(4-methoxyphenyl)-4-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrido[2,3-b]pyrin-3-yl)propionyl)indol-3-yl)piperazinyl)but-2-ene-1,4-dione (L31)

[0325] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L3 (80 mg, 0.23 mmol) and intermediate 68 (140 mg, 0.3 mmol) were used as raw materials to synthesize L31 (34 mg, 21%).

[0326] Example 32: Synthesis of (E)-2-cyano-3-cyclopropyl-N-(2-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionamido)ethyl)acrylamide (L32)

[0327]

[0328] Step 1: Synthesis of tert-butyl (2-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionamido)ethyl)carbonate (69)

[0329] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 69 (60 mg, 53%) was synthesized using L3 (80 mg, 0.23 mmol) and N-BOC-ethylenediamine (48 mg, 0.3 mmol) as raw materials.

[0330] Step 2: Synthesis of N-(2-aminoethyl)-3-(2-(5-methyl[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (70)

[0331] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 70 (60 mg, 0.12 mmol) was synthesized using Intermediate 69 (60 mg, 0.12 mmol) as a starting material.

[0332] Step 3: Synthesis of (E)-2-cyano-3-cyclopropyl-N-(2-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionamido)ethyl)acrylamide (L32)

[0333] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L32 (17 mg, 27%) was synthesized using intermediate 70 (60 mg, 0.12 mmol) and (E)-2-cyano-3-cyclopropylacrylic acid (21 mg, 0.15 mmol) as raw materials.

[0334] Example 33: Synthesis of (E)-3-cyclopropyl-2-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazine-1-formyl)acrylonitrile (L33)

[0335]

[0336] Step 1: Synthesis of tert-butyl 4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazine-1-carboxylate (71)

[0337] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 71 (100 mg, 83%) was synthesized using L3 (80 mg, 0.23 mmol) and N-BOC-piperazine (34 mg, 0.18 mmol) as raw materials.

[0338] Step 2: Synthesis of 1-(piperidin-1-yl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-propanone (72)

[0339] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 72 (100 mg, 0.2 mmol) was synthesized using Intermediate 71 (100 mg, 0.2 mmol) as a starting material.

[0340] Step 3: Synthesis of (E)-3-cyclopropyl-2-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazine-1-carbonyl)acrylonitrile (L33)

[0341] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L33 (17 mg, 21%) was synthesized using intermediate 72 (100 mg, 0.2 mmol) and (E)-2-cyano-3-cyclopropylacrylic acid (21 mg, 0.15 mmol) as raw materials.

[0342] Example 34: Synthesis of (E)-2-cyano-3-cyclopropyl-N-(2-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionyl)piperazin-1-yl)ethyl)acrylamide (L34)

[0343]

[0344] Step 1: Synthesis of 1-(4-(2-aminoethyl)piperazin-1-yl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanone (30)

[0345] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 30 (100 mg, 0.18 mmol) was synthesized using intermediate 29 (100 mg, 0.18 mmol) as a starting material.

[0346] Step 2: Synthesis of (E)-2-cyano-3-cyclopropyl-N-(2-(4-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propionyl)piperazin-1-yl)ethyl)acrylamide (L34)

[0347] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L34 (20 mg, 19%) was synthesized using intermediate 30 (100 mg, 0.18 mmol) and (E)-2-cyano-3-cyclopropylacrylic acid (25 mg, 0.18 mmol) as raw materials.

[0348] Example 35: Synthesis of (E)-3-cyclopropyl-2-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)aziridine-3-yl)piperazine-1-carbonyl)acrylonitrile (L35)

[0349]

[0350] Step 1: Synthesis of (E)-2-cyano-3-cyclopropylacrylic acid (74)

[0351] Add cyanoacetic acid (1 g, 12 mmol) and 12 mL of pyridine into a flask, then add cyclopropanecarboxaldehyde 73 (925 mg, 13.2 mmol) and tetrahydropyrrole (240 μL, 2.9 mmol), and stir at room temperature for 3 h. Monitor the reaction by TLC. After the reaction is complete, add 10 mL of 6 M hydrochloric acid solution into the reaction solution, stir for 10 min, then add water (15 mL) and ethyl acetate (15 mL), extract three times, combine the organic layers, dry over anhydrous Na2SO4, filter and spin dry to obtain intermediate 74 (1.4 g, 88%) as a white solid.

[0352] Step 2: Synthesis of tert-butyl (E)-4-(2-cyano-3-cyclopropylacryloyl)piperazine-1-carboxylate (75)

[0353] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 75 (3.4 g, 76%) was synthesized using intermediate 74 (3.6 g, 19 mmol) and N-BOC-piperazine (2 g, 14.6 mmol) as raw materials.

[0354] Step 3: Synthesis of (E)-3-cyclopropyl-2-piperazine-1-carbonyl acrylonitrile (76)

[0355] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 76 (700 mg, 2.3 mmol) was synthesized using Intermediate 75 (700 mg, 2.3 mmol) as a starting material.

[0356] Step 4: Synthesis of tert-butyl (E)-3-(4-(2-cyano-3-cyclopropylacryloyl)piperazin-1-yl)aziridine-1-carboxylate (77)

[0357] Referring to the method for synthesizing intermediate 47 from intermediate 37 in Example 22, intermediate 76 (700 mg, 2.3 mmol) and 1-Boc-3-azetidinone (788 mg, 4.6 mmol) were used as raw materials to synthesize intermediate 77 (422 mg, 51%).

[0358] Step 5: Synthesis of (E)-2-(4-(aziridine-3-yl)piperazine-1-carbonyl)-3-cyclopropylacrylonitrile (78)

[0359] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 78 (422 mg, 1.2 mmol) was synthesized using Intermediate 77 (422 mg, 1.2 mmol) as a starting material.

[0360] Step 6: Synthesis of (E)-3-cyclopropyl-2-(4-(1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)aziridine-3-yl)piperazine-1-carbonyl)acrylonitrile (L35)

[0361] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L3 (100 mg, 0.3 mmol) and intermediate 78 (83 mg, 0.23 mmol) were used as raw materials to synthesize L35 (15 mg, 11%).

[0362] Example 36: Synthesis of (E)-3-cyclopropyl-2-(4-((1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-4-yl)methyl)piperazine-1-carbonyl)acrylonitrile (L36)

[0363]

[0364] Step 1: Synthesis of (E)-3-cyclopropyl-2-piperazine-1-carbonyl acrylonitrile (76)

[0365] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 76 (700 mg, 2.3 mmol) was synthesized using Intermediate 75 (700 mg, 2.3 mmol) as a starting material.

[0366] Step 2: Synthesis of tert-butyl (E)-4-((4-(2-cyano-3-cyclopropylacryloyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (79)

[0367] Referring to the method for synthesizing intermediate 47 from intermediate 37 in Example 22, intermediate 76 (700 mg, 2.3 mmol) and 1-tert-butyloxycarbonylpiperidine-4-carboxaldehyde (289 mg, 4.6 mmol) were used as raw materials to synthesize intermediate 79 (398 mg, 43%).

[0368] Step 3: Synthesis of (E)-3-cyclopropyl-2-(4-(piperidin-4-ylmethyl)piperazine-1-carbonyl)acrylonitrile (80)

[0369] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 80 (398 mg, 1 mmol) was synthesized using Intermediate 79 (398 mg, 1 mmol) as a starting material.

[0370] Step 4: Synthesis of (E)-3-cyclopropyl-2-(4-((1-(3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl)piperazin-4-yl)methyl)piperazine-1-carbonyl)acrylonitrile (L36)

[0371] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L3 (90 mg, 0.25 mmol) and intermediate 80 (80 mg, 0.2 mmol) were used as raw materials to synthesize L36 (13 mg, 10%).

[0372] Example 37: Synthesis of N-(2-(2-(adamantan-1-yl)acetamido)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L37)

[0373]

[0374] Step 1: Synthesis of tert-butyl (2-(2-(adamantan-1-yl)acetamido)ethyl)carbamate (82)

[0375] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 82 (205 mg, 61%) was synthesized using 81 (194 mg, 1 mmol) and N-BOC-ethylenediamine (208 mg, 1.3 mmol) as raw materials.

[0376] Step 2: Synthesis of adamantane-1-yl-2-aminoethyl)acetamide (83)

[0377] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 83 (205 mg, 0.61 mmol) was synthesized using Intermediate 82 (205 mg, 0.61 mmol) as a starting material.

[0378] Step 3: Synthesis of N-(2-(2-(adamantan-1-yl)acetamido)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L37)

[0379] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L3 (80 mg, 0.23 mmol) and intermediate 83 (98 mg, 0.3 mmol) were used as raw materials to synthesize L37 (36 mg, 27%).

[0380] Example 38: Synthesis of 1-(4-(2-adamantan-1-yl)acetyl)piperazin-1-yl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetone (L38)

[0381]

[0382] Step 1: Synthesis of tert-butyl 4-(2-(adamantan-1-yl)acetyl)piperidine-1-carboxylate (84)

[0383] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 84 (2.5 g, 67%) was synthesized using 81 (2 g, 10.3 mmol) and N-BOC-piperazine (2.5 g, 13.4 mmol) as raw materials.

[0384] Step 2: Synthesis of 1-(piperazin-1-yl)-2-(adamantyl)ethanone (85)

[0385] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 85 (150 mg, 0.42 mmol) was synthesized using intermediate 84 (150 mg, 0.42 mmol) as a starting material.

[0386] Step 3: Synthesis of 1-(4-(2-adamantan-1-yl)acetyl)piperazin-1-yl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanone (L38)

[0387] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L3 (80 mg, 0.23 mmol) and intermediate 85 (108 mg, 0.3 mmol) were used as raw materials to synthesize L38 (37 mg, 31%).

[0388] Example 39: Synthesis of N-(2-(4-(2-(adamantan-1-yl)acetyl)piperazin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L39)

[0389]

[0390] Step 1: Synthesis of tert-butyl (2-(4-(2-(adamantan-1-yl)acetyl)piperazin-1-yl)ethyl)carboxylate (86)

[0391] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, intermediate 86 (230 mg, 57%) was synthesized using 81 (195 mg, 1 mmol) and 1-[2-(BOC-amino)ethyl]piperazine (299 mg, 1.3 mmol) as raw materials.

[0392] Step 2: Synthesis of 1-(4-(2-aminoethyl)piperazin-1-yl)-2-(adamantan-1-yl)ethanone (87)

[0393] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 87 (230 mg, 0.57 mmol) was synthesized using Intermediate 86 (230 mg, 0.57 mmol) as a starting material.

[0394] Step 3: Synthesis of N-(2-(4-(2-(adamantan-1-yl)acetyl)piperazin-1-yl)ethyl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)propanamide (L39)

[0395] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L3 (80 mg, 0.23 mmol) and intermediate 87 (121 mg, 0.3 mmol) were used as raw materials to synthesize L39 (24 mg, 16%).

[0396] Example 40: Synthesis of adamantyl-1-yl-2-(4-(adamantyl-1-yl-2-acetylpiperazinyl)-3-azetidinyl-1-yl-1-yl-3-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetone (L40)

[0397]

[0398] Step 1: Synthesis of 1-(piperazin-1-yl)-2-(adamantyl)ethanone (85)

[0399] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 85 (3 g, 8 mmol) was synthesized using intermediate 84 (3 g, 8 mmol) as a starting material.

[0400] Step 2: Synthesis of tert-butyl 3-(4-(2-(adamantyl-1-yl)acetylpiperazin-1-yl)azetidine-1-carboxylate (88)

[0401] Referring to the method for synthesizing Intermediate 47 from Intermediate 37 in Example 22, Intermediate 88 (451 mg, 47%) was synthesized using Intermediate 85 (800 mg, 2.3 mmol) and 1-Boc-3-azetidinone (768 mg, 4.6 mmol) as raw materials.

[0402] Step 3: Synthesis of adamantyl-1-yl-2-(3-azetidinyl-1-yl-4-piperazin-1-yl)ethanone (89)

[0403] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 89 (451 mg, 1.1 mmol) was synthesized using Intermediate 88 (451 mg, 1.1 mmol) as a starting material.

[0404] Step 4: Synthesis of adamantyl-1-yl-2-(4-(adamantyl-1-yl-2-acetylpiperazinyl)-3-azetidinyl-1-yl-1-yl-3-2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetone (L40)

[0405] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L40 (41 mg, 27%) was synthesized using L3 (80 mg, 0.23 mmol) and intermediate 89 (162 mg, 0.3 mmol) as raw materials.

[0406] Example 41: Synthesis of 1-(4-((4-(2-(adamantan-1-yl)acetylpiperazin-1-yl)methyl)piperidin-1-yl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetone (L41)

[0407]

[0408] Step 1: Synthesis of 1-(piperazin-1-yl)-2-(adamantyl)ethanone (85)

[0409] Referring to the method for synthesizing intermediate 35 from intermediate 34 in Example 16, intermediate 85 (3 g, 8 mmol) was synthesized using intermediate 84 (3 g, 8 mmol) as a starting material.

[0410] Step 2: Synthesis of tert-butyl 4-((4-(2-(adamantan-1-yl)-acetylpiperazin-1-yl)methylpiperidin-1-yl)carboxylate (90)

[0411] Referring to the method for synthesizing Intermediate 47 from Intermediate 37 in Example 22, Intermediate 90 (463 mg, 42%) was synthesized from Intermediate 85 (800 mg, 2.3 mmol) and 1-tert-butyloxycarbonylpiperidine-4-carboxaldehyde (1.1 g, 4.8 mmol) as raw materials.

[0412] Step 3: Synthesis of 1-piperidin-4-methylpiperazine-1-ethyl-2-adamantyl-1-ethanone (91)

[0413] Referring to the method for synthesizing Intermediate 35 from Intermediate 34 in Example 16, Intermediate 91 (463 mg, 1 mmol) was synthesized using Intermediate 90 (463 mg, 1 mmol) as a starting material.

[0414] Step 4: Synthesis of 1-(4-((4-(2-(adamantan-1-yl)acetylpiperazin-1-yl)methyl)piperidin-1-yl)-3-(2-(5-methyl-[1,1'-biphenyl]-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetone (L41)

[0415] Referring to the method for synthesizing L16 from intermediate L3 and intermediate 35 in Example 16, L41 (40 mg, 23%) was synthesized using L3 (90 mg, 0.25 mmol) and intermediate 91 (148 mg, 0.32 mmol) as raw materials.

[0416] The following experimental examples demonstrate the beneficial effects of the 7-azaindole compounds provided by the embodiments of the present disclosure.

[0417] Experimental Example 1: Binding constant evaluation experiment of the fluorescence polarization probes L10-L15 provided by the present disclosure and the CSN5 enzyme

[0418] 1. Experimental materials: WHB all-black 96-well flat-bottom luminescent plate (specification: WHB-96-02), WHB 96-well cell culture plate (specification: WHB-96), Ni-NTA column, low-temperature and high-pressure continuous flow cell disruptor, and microplate reader.

[0419] 2. Experimental methods:

[0420] The protein expression and purification steps are as follows: the recombinant plasmid is transferred into Escherichia coli Transetta (DE3) for expression, cultured at 37°C until OD600 reaches 0.6-0.8, the temperature is lowered to 18°C ​​(CSN5), and a final concentration of 0.3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) is added to induce the expression of the target protein, and the culture is continued for 18-20 hours. The next day, the bacteria are collected by centrifugation at 4000 rpm for 30 minutes, and resuspended in lysis buffer A (Buffer A is 20 mM Tris, 200 mM NaCl, pH 8.0), and the bacteria are lysed with a low-temperature high-pressure continuous flow cell disruptor (JNBIO), and then centrifuged at 12000 rpm for 30 minutes to remove cell debris, collect the supernatant and purify it using a Ni-NTA affinity chromatography column (Roche). Before protein purification, the Ni-NTA column was pretreated: residual protein was eluted with 10 mL Buffer B (the other components of the original Buffer A remained unchanged, and 500 mM imidazole was added), then rinsed with 20 mL milliQ water, and finally the affinity column was equilibrated with 20 mL Buffer A. The collected supernatant was added to the Ni-NTA column, and after the supernatant was completely passed through the Ni-NTA column, it was gradient eluted with Buffer C with different concentrations of imidazole to remove non-specifically bound proteins and weakly bound proteins. Finally, the target protein was eluted with Buffer D containing 250 mM imidazole (the other components of the original Buffer A remained unchanged, and 250 mM imidazole was added). The eluted target protein was collected and concentrated using Amicon Ultra 10K (Millipore), and then the target protein was replaced into the corresponding buffer using the desalting column Hi Trap Desalting column (GE Healthcare). All steps in the purification process were monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAG), and the protein concentration was determined by Nanno Drop 2000 spectrophotometer (Thermo Scientific). The protein was finally snap-frozen in liquid nitrogen and stored at -80°C for subsequent enzyme kinetic experiments.

[0421] K d The experimental steps for value testing are:

[0422] The CSN5 enzyme solution was diluted threefold with test buffer (20 mM Tris, 200 mM NaCl, pH 7.5, 0.01% Triton) to ten concentrations. Then, 40 μL of buffer solution and 10 μL of diluted enzyme solution were added to each test well in turn, and then 10 μL of pre-prepared fluorescent substrate solution (final concentration of 0.25 μM) was added. Three replicate wells were set in parallel for each group. The total volume of the reaction system was 60 μL. The cells were incubated at room temperature for 1 h, and then detected using an enzyme reader. The changes in fluorescence polarization values ​​were fitted using GraphPad Prism software to obtain K d value.

[0423] 3. Experimental results:

[0424] The 7-azaindole compounds L10 to L15 provided in the present invention are compounds containing fluorescent groups. We use these fluorescent compounds to establish an enzyme activity screening system based on fluorescence polarization technology. A compound containing a fluorescent group that binds strongly to the active site of CSN5 is selected as a fluorescence polarization substrate. When the substrate binds to CSN5, it can show a strong fluorescence polarization signal. The inhibitor, the fluorescent substrate and the CSN5 protein are co-incubated, and the two ligands competitively bind to the CSN5 protein. If the inhibitor has a higher affinity with the protein, the polarization signal is weak; otherwise, the polarization signal is stronger. We measured the binding constants of these six fluorescent substrates, and the results are shown in Table 1. It can be seen that L10 to L15 have a strong binding affinity with the CSN5 subunit, among which the compound with ethylenediamine as the connecting fragment has the strongest affinity, K d Based on the optimized fluorescence polarization experimental conditions, we used the fluorescent substrate L10 to test the IC of the reported CSN5 inhibitor Ⅰ-12 and CSN5 subunits. 50 The value was 1.04 μM, which verified the sensitivity and accuracy of the fluorescence polarization substrate L10 for screening CSN5 inhibitors.

[0425] Table 1 Determination of binding constants of L10-L15 and CSN5 (K d )

[0426]

[0427] Experimental Example 2: In vitro inhibitory activity, cell proliferation inhibitory activity or degradation activity test of the 7-azaindole compounds provided by the present disclosure on CSN5 enzyme

[0428] 1. Experimental materials: WHB all-black 96-well flat-bottom luminescent plate (specification: WHB-96-02), WHB 96-well cell culture plate (specification: WHB-96), 6-well cell culture plate, sterile pipette tip, sterile centrifuge tube.

[0429] 2. Experimental Methods

[0430] The experimental steps for in vitro enzyme activity test are as follows:

[0431] All inhibitor compounds were dissolved in DMSO to prepare a 100mM stock solution for standby use. At room temperature (25°C), the inhibition rate of single-concentration target compounds (100mM and 10mM) on CSN5 was tested in a 96-well all-black ELISA plate. First, 3 replicate wells were set up, and 10μL of compound working solution, 30μL of buffer solution and 10μL of enzyme solution were added to each test well in turn. Incubate for 10 minutes, then add 10μL of pre-prepared fluorescent substrate solution (final concentration of 0.25μM) to a total volume of 60μL of the reaction system, incubate for another 1h, and then use a fluorescence polarization detector for detection. The inhibition rate of the tested compound at a single concentration was calculated using Excel software based on the change in fluorescence polarization, and then compounds with an inhibition rate greater than 50% were selected for IC 50 The IC value of the inhibitor compound was obtained by plotting the relationship between activity and inhibitor concentration using software. 50 Three parallel groups were set for each concentration.

[0432] The experimental steps for testing HCT116 cell proliferation inhibition activity are as follows:

[0433] Collect cells in the logarithmic phase, adjust the concentration of the cell suspension, add 100 μL to each well, and plate. Incubate at 5% CO2 and 37°C until the cell monolayer is spread on the bottom of the well (96-well flat-bottom plate). After attaching to the wall, take out the 96-well plate, discard the original culture medium, add the drug, put the cells into the incubator, incubate at 5% CO2 and 37°C for 24 hours, and observe under an inverted microscope. After the drug effect ends, add 20 μL MTT to each well and continue to culture for 3 hours. Terminate the culture and carefully remove the culture medium in the well. Add 100 μL DMSO to each well, place it on a shaker and shake at low speed for 10 minutes to fully dissolve the crystals, and measure the absorbance of each well under an ELISA reader.

[0434] The experimental steps for the degradation activity test are as follows:

[0435] HCT116 cells were cultured in a 6-well cell culture plate, and different concentrations of drugs were added to the culture plate and incubated. The old culture medium was discarded, washed twice with PBS, the PBS was discarded, and RIPA was added. After the lysis was completed, the cells in the well plate were transferred to a 1.5mL EP tube with a cell scraper, and further broken with a cell wall disruptor. After the wall breaking was completed, centrifugation was performed (12000rpm, 4℃, 10min), and 10μL of the supernatant was taken and diluted to 100μL with PBS (diluted 10 times) for BCR quantification. Most of the supernatant was marked with a volume, SDS loading buffer was added, and it was placed in a 1.5mL EP tube and placed at 95℃ for 20min to denature the protein and bind to SDS. 20μL of protein standard solution of different concentrations was added in sequence, and then 20μL of sample was added. Then 200μL of BCA working solution was added to each well, shaken on a shaker for 5min, and placed in a 37℃ oven for 30min for incubation. Finally, the absorbance was detected at a wavelength of 562nm using an ELISA reader to obtain the standard protein concentration curve and the absorbance of each well sample, and the original protein concentration was inferred by the dilution multiple, followed by protein quantification to ensure that the total amount of protein loaded in each well was consistent. After loading, the electrophoresis, membrane transfer, membrane cutting, blocking, incubation with primary antibody, incubation with secondary antibody, and finally color development were performed.

[0436] To further evaluate the activity of compounds L16 to L41 at the cellular level, we tested the effects of these 26 compounds on the proliferation activity of the CSN5-overexpressing cell line HCT116 using the MTT assay.

[0437] 3. Experimental results:

[0438] Through the above experimental methods, the inhibitory activity of L3-L4, L9, L16-L41 on CSN5 enzyme and the effect of L16-L41 on HCT116 proliferation activity were tested. 50 The values ​​are shown in Table 2 (three parallel tests, the experimental results are averaged, and the error is between 5% and 10%).

[0439] Table 2 Effects of L3-L4, L9, L16-L41 on the inhibitory activity of CSN5 enzyme and L16-L41 on the inhibitory activity of HCT116 (IC 50 ) a

[0440]

[0441]

[0442] The results of the CSN5 in vitro enzyme activity test in Table 2 show that most of the compounds provided by the present disclosure have good CSN5 inhibitory activity. Compounds L1 to L9 are small molecule compounds. Preliminary analysis shows that L3 (IC 50=14.97μM) had good activity. Compounds L16-L41 were potential degraders and showed good enzyme activity inhibition in the preliminary enzyme activity evaluation experiment; the compounds L16-L26 containing pomalidomide structure with C4 as the connection site generally had higher enzyme activity than the compounds with C5 as the connection site; the compounds L27-L31 containing p-methoxyphenyl fumaric acid structure had good enzyme activity overall, IC 50 The values ​​were all less than 4 μM, among which compound L27 had the best enzyme activity (IC 50 =1.63 μM); Compounds L27 to L31 containing cyanoacrylamide fragments also had good enzyme activity, and compound IC 50 The values ​​were all less than 10 μM; the enzyme activities of compounds L37 to L41 containing adamantane structures were quite different.

[0443] To further evaluate the activity of the degraders at the cellular level, we tested the effects of 26 potential degraders, including compounds L16 to L41, on the proliferation activity of the highly expressed CSN5 cell line HCT116 by MTT assay. As can be seen from Table 2, compounds containing p-methoxyphenyl fumaric acid structure showed good inhibitory activity, which was consistent with the enzyme activity results, including compound L28 (IC 50 =0.54 μM), L29 (IC 50 =2.8μM), L30 (IC 50 =3.88 μM) and L31 (IC 50 =1.57 μM); however, the compounds containing pomalidomide structure showed weak inhibitory activity against HCT116 cells, IC 50 The values ​​were all above 30μM; among the compounds containing cyanoacrylamide, L36 (IC 50 =23.21 μM) showed weak inhibitory activity. Some compounds containing adamantane structure showed moderate inhibitory activity.

[0444] Experimental Example 3: Preliminary evaluation of the degradation potential of 7-azaindole compounds provided by the present disclosure on cell CSN5

[0445] Based on enzyme activity and cell activity, we selected some compounds (L20, L22, L27, L28, L29, L31, L34, L36, L37, L40) and used Western Blot to detect the effects of these compounds at a concentration of 10 μM on the catalytic activity of the CSN complex and the degradation activity of the CSN5 subunit in HCT116 cells for 16 h. Figure 1As shown in the figure, it can be observed that compared with the DMSO control group, positive compounds Ⅰ-12, L20, L22, etc. showed a significant inhibitory effect on the catalytic activity of the COP9 complex, blocking the de-NEDD8ization of Cullin1 protein, resulting in a significant increase in Cullin1-NEDD8 protein. This is consistent with the cell proliferation inhibition activity (IC 50 >100μM). It is speculated that L20 and L22 have weak inhibitory effects on the catalytic activity of the COP9 complex, which is not enough to kill cells and do not show proliferation inhibition effect. The compound L28 (HCT116, IC 50 =0.56 μM) and L31 (HCT116, IC 50 =1.57μM) did not show a significant increase in Cullin1-NEDD8 protein. We speculate that this series of compounds is likely to show a strong inhibitory effect on cell proliferation through the p-methoxyphenylfumaric acid structure and other targets, rather than interacting with COP9. We then examined the effects of these compounds on CSN5 content; the selected compounds did not show the potential to significantly degrade CSN5 subunits. Due to the large differences in CSN5 subunits and variants in other cell lines, these potential degraders may play a role in the degradation of CSN5.

[0446] In summary, the present disclosure provides a 7-azaindole compound that can be used as a fluorescence polarization probe or degradation chemical probe targeting CSN5; wherein, the fluorescence polarization chemical probe has a good binding affinity with the metalloprotease CSN5, and we have established a CSN5 inhibitor screening system based on this, which has high accuracy and ease of operation, solves the problem that it is difficult to establish an in vitro activity system for CSN5, and lays an important foundation for the discovery of new CSN5 inhibitors; at the same time, the degradation chemical probe exhibits good enzyme level activity and cell inhibitory activity, and has the potential to degrade CSN5 protein and variants, providing a material basis for the development of drugs targeting CSN5 and the study of biological functions, and at the same time has great potential in the discovery of cancer immunotherapy drugs and the treatment of other related diseases.

[0447] The above is only a preferred embodiment of the present disclosure. It should be understood that the present disclosure is not limited to the form disclosed herein, and should not be regarded as excluding other embodiments, but can be used in various other combinations, modifications and environments, and can be modified within the scope of the concept described herein through the above teachings or the technology or knowledge of the relevant field. The changes and modifications made by those skilled in the art do not deviate from the spirit and scope of the present disclosure, and should be within the scope of protection of the claims attached to the present disclosure.

Claims

1. A 7-azaindole compound, characterized in that: The 7-azaindole compound has a structure as shown in Formula I: In the formula, R1 is selected from phenyl, pyridyl or thienyl; L is selected from as well as wherein X is selected from a hydrogen atom, an alkyl group, 5-fluorescein isothiocyanate, or a protein ligand of an E3 ubiquitin ligase complex.

2. The 7-azaindole compound according to claim 1, characterized in that X is selected from the protein ligand, and the protein ligand is selected from as well as One of them.

3. The 7-azaindole compound according to claim 1 or 2, characterized in that: L is selected from as well as One of them.

4. The 7-azaindole compound according to claim 1, characterized in that R1 is selected from the phenyl group.

5. The 7-azaindole compound according to claim 1, characterized in that: X is selected from the hydrogen atom.

6. The 7-azaindole compound according to claim 1 or 5, characterized in that: L is selected from as well as One of them.

7. The 7-azaindole compound according to claim 1, characterized in that The 7-azaindole compound has a structure as shown in any one of Formula L1 to Formula L41:

8. A method for synthesizing a 7-azaindole compound according to any one of claims 1 to 7, characterized in that: The following steps are involved: S1. Compound 1 and compound 2 are subjected to substitution reaction to obtain compound 3; S2. The 7-azaindole compound I is synthesized based on the compound 3.

9. Use of the 7-azaindole compound according to any one of claims 1 to 7 or the method according to claim 8 in the preparation of anticancer drugs.

10. The use according to claim 9, characterized in that The 7-azaindole compounds are used for screening and / or preparing CSN5 inhibitors.

Citation Information

Patent Citations

  • (aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor

    CN101910127A

  • 7-azaindole heterocyclic compound and preparation method and application thereof

    CN113461683A

  • Isoindoline compound, preparation method, pharmaceutical composition and application

    CN116496246A

  • Compositions and methods for JAMM protein inhibition

    US20140235548A1